Hiroshima University

Fumakilla Limited

Sharp Kabushiki Kaisha Corporation

Amateraspharma Inc.

Suntory Limited

Seiko Shigeta

Kazuhisa Ono

Satoru Oka

Takeshi Wada

Hideo Nojima

Tetsuya Yoneda

Kazuo Nishikawa

Seiji Kawamoto

Shigeru Goto

Shuji Sato

Takeshi Goto

Masatoshi Oshita

Kengo Akimoto

Tsunehiro Aki

Osamu Suzuki

A method of evaluating performance of an activation gas deactivating an antigenic substance including the steps of causing the antigenic substance and the activation gas to react with each other, to obtain a processed antigenic substance, and causing an antibody against the antigenic substance with the processed antigenic substance to measure binding activity of the processed antigenic substance with the antibody is provided, whereby an evaluation method that can accurately and easily evaluate performance of an activation gas deactivating an antigenic substance is provided.

Method of evaluating performance of activation gas deactivating antigenic substance and apparatus for generating processed antigenic substance used as evaluation sample of the evaluating method

The present invention relates to a method of deactivating an antigenic substance by causing positive and negative ions to act on the antigenic substance, and the positive and negative ions are caused to act in an atmosphere in which each of positive ion concentration and negative ion concentration is at least about 50,000/cm, and more preferably, at least about 100,000/cm.

Method and apparatus for deactivating antigenic substance through positive and negative ions functions

The present invention discloses anti-histone H1 monoclonal antibodies, hybridomas for the production thereof, and polypeptides, which are useful for suppressing, predicting, or diagnosing transplant rejection in organ transplantation.

Anti-histone H1 monoclonal antibody and hybridoma for the production thereof

Polypeptide that binds anti-histone H1 antibody

A method for producing highly unsaturated fatty acids comprising culturing a microorganism, belonging to the genusand having resistance to a carbon source, in a medium having a carbon source concentration of at least 4% by weight, and collecting highly unsaturated fatty acids from the cultured products. Culturing the microorganism for about a week gives at least about 7 g/L of highly unsaturated fatty acids.

Method for producing highly unsaturated fatty acids and lipid containing same

The present invention is directed to novel purified and isolated mite allergens possessing mite allergen activity with a molecular weight of about 94,000, about 40,000, about 16,000 or about 14,000 as determined by SDS-PAGE, which can be isolated from extracts of mites, and to a process for producing such mites allergens. The purified and isolated mite allergens of the present invention are useful as a pharmaceutical and a diagnostic composition for mite allergic diseases.

Purified mite allergen

New purified mite allergens useful as pharmaceutical and diagnostic compositions for the treatment and diagnosis of mite allergic diseases are provided. Both allergens are contained in fecal extracts of mites in culture. The high molecular weight allergen has a weight average molecular weight of 70,000 to 80,000 as determined by sedimentation equilibrium. This is a glycoprotein containing more than about 70% sugar, and possesses allergen activity. The low molecular weight antigen has a molecular weight of 1,500 to 5,000 as determined by Sephadex G25 gel filtration. This is a glycoprotein containing more than about 40% sugar, and also possesses allergen activity.

Low molecular weight allergen obtained from Dermatophagoides farinae

The present invention is directed to novel purified and isolated mite allergens possessing mite allergen activity with a molecular weight of about 94,000, about 40,000, about 16,000 or about 14,000 as determined by SDS-PAGE, which can be isolated from extracts of mite, and to a process for producing such mite allergens. The purified and isolated mites allergens of the present invention are useful as a pharmaceutical and a diagnostic composition for mite allergic diseases.

The present invention is directed to a recombinant mite allergen obtainable by expression of a mite-body-derived gene, a gene which codes for said allergen, a mite allergen fragment, a polypeptide having an epitope contained in said allergen, an expression vector capable of expressing the gene, a bacterium, yeast or mammalian cell transformed with said expression vector, a method for producing said allergen, and a pharmaceutical composition or a diagnostic reagent for the treatment of mite allergic diseases.

Growing community of inventors

Hiroshima, Japan

Seiko Shigeta